A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Takeda

Status and phase: Enrolling; Phase 3

Conditions: Generalized Pustular Psoriasis; Erythrodermic Psoriasis

Treatments: Drug: TAK-279

Study type: Interventional

Funder types: Industry

Identifiers

NCT06323356

TAK-279-PsO-3005

jRCT2031230714 (Registry Identifier)

Details and patient eligibility

About

The main aim of this study is to check if TAK-279 improves symptoms of With Generalized Pustular Psoriasis (GPP) or Erythrodermic Psoriasis (EP) and side effect from the study treatment or TAK-279.

All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules.

Participants will be in the study for up to 61 weeks including 52 weeks of study treatment. During the study, participants will visit their study clinic for multiple times.

Enrollment: 20 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. A diagnosis of GPP or EP prior to the screening visit.
2. Candidate for phototherapy or systemic therapy.

Exclusion criteria

1. Other forms of psoriasis.
2. History of recent infection.
3. Any prior exposure to TAK-279, or participation in any study that included a TYK2 inhibitor.

Other protocol defined inclusion/exclusion criteria apply.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

20 participants in 2 patient groups

TAK-279 for Generalized Pustular Psoriasis

Experimental group

Description:

Participants with generalized pustular psoriasis will receive TAK-279 from Day 1 up to Week 52.

Treatment:

Drug: TAK-279

TAK-279 for Erythrodermic Psoriasis

Experimental group

Description:

Participants with erythrodermic psoriasis will receive TAK-279 from Day 1 up to Week 52.

Treatment:

Drug: TAK-279